To determine a positive result with either dose, the early-start

To determine a positive result with either dose, the early-start treatment group had to meet each of three hierarchical end points of the primary analysis based on the Unified Parkinson’s Disease Rating Scale (UPDRS, a 176-point scale, with higher numbers indicating more severe disease): superiority to placebo in the rate of change in the UPDRS score between weeks 12 and 36, superiority to delayed-start treatment in the change in the score between baseline and week 72, and noninferiority to delayed-start treatment in the rate of change in the score between weeks 48 and 72.

Results

Early-start treatment with rasagiline

at a dose of 1 mg per day met all end points in the primary analysis: a smaller mean (+/- SE) increase ( rate of worsening) in the UPDRS score between weeks selleck screening library 12 and 36 (0.09 +/- 0.02 points per learn more week in the early-start group vs. 0.14 +/- 0.01 points per week in the placebo group, P=0.01), less worsening in the score between baseline

and week 72 (2.82 +/- 0.53 points in the early-start group vs. 4.52 +/- 0.56 points in the delayed-start group, P=0.02), and noninferiority between the two groups with respect to the rate of change in the UPDRS score between weeks 48 and 72 (0.085 +/- 0.02 points per week in the early-start group vs. 0.085 +/- 0.02 points per week in the delayed-start group, P<0.001). All three end points were not met with rasagiline at a dose of 2 mg per day, since the change in the UPDRS score between baseline and week 72 was not significantly different in the two groups (3.47 +/- 0.50 points in the early-start group and 3.11 +/- 0.50 points in the delayed-

start group, P=0.60).

Conclusions

Early VE-822 molecular weight treatment with rasagiline at a dose of 1 mg per day provided benefits that were consistent with a possible disease-modifying effect, but early treatment with rasagiline at a dose of 2 mg per day did not. Because the two doses were associated with different outcomes, the study results must be interpreted with caution. (ClinicalTrials. gov number, NCT00256204.)”
“Rapid depletion of memory CD4(+) T cells and delayed induction of neutralizing antibody (NAb) responses are characteristics of human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) infections. Although it was speculated that postinfection NAb induction could have only a limited suppressive effect on primary HIV replication, a recent study has shown that a single passive NAb immunization of rhesus macaques 1 week after SIV challenge can result in reduction of viral loads at the set point, indicating a possible contribution of postinfection NAb responses to virus control. However, the mechanism accounting for this NAb-triggered SIV control has remained unclear.

Comments are closed.